Hong Kong Fintech News, Cryptocurrency Stories, Business Press Releases

Everest Medicines’ New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access

HONG KONG, Aug 14, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, “Everest”) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY(R) (etrasimod) for the treatment of patients with moderately to severely active ulcerative colitis (UC). Building on prior approvals in Singapore, […]

Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million

HONG KONG, Aug 14, 2025 – (ACN Newswire via SeaPRwire.com) – Yuexiu Real Estate Investment Trust (“Yuexiu REIT”, together with Yuexiu REIT Asset Management Limited, collectively known as the “REIT”; stock code: 405) announced its interim results for the six months ended 30 June 2025. Yuexiu REIT Management Team: Chairman and Non-Executive Director Mr. JIANG […]

The 35th Food Expo opens today

HONG KONG, Aug 14, 2025 – (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the five-day (14-18 August) Food Expo, Beauty & Wellness Expo and Home Delights Expo open to the public from today at the Hong Kong Convention and Exhibition Centre. The Food Expo PRO, held concurrently from 14 to 16 August, is […]

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

HONG KONG, Aug 15, 2025 – (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the “Updated Guidelines”). Etrasimod, an S1P receptor modulator, is recommended for the induction of remission in patients with moderately to severely active UC and for […]

OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively

Results Highlights: – Revenue reached US$83.6 million, a year-on-year increase of 5.9%.– Sales volume reached 919,000 units, of which 779,000 units were proprietary products, representing a year-on-year increase of 8.6%.– Profit attributable to owners of the company increased by 5.1% year-on-year to US$19.8 million.– Core operating profit amounted to US$15.1 million, an increase of 11.4% […]

艾曲莫德入選《2025 ACG臨床指南:成人潰瘍性結腸炎》,獲強烈推薦用於中重度潰瘍性結腸炎的誘導緩解及維持緩解治療

香港, 2025年8月15日 – (亞太商訊 via SeaPRwire.com) – 雲頂新耀今日宣布,旗下創新藥艾曲莫德(VELSIPITY(R),etrasimod)被納入《2025 ACG 臨床指南:成人潰瘍性結腸炎》(下稱「新版指南」),並獲得強烈推薦用於中重度活動性潰瘍性潰瘍性結腸炎…

How Do AI Workflow Automations Work?

SINGAPORE, Aug 16, 2025 – (ACN Newswire via SeaPRwire.com) – A 2022 survey from Vanson Bourne revealed that around 91%1 of respondents saw increased demand for automation from business teams. As AI technology evolves, that demand will only grow. AI automations can help organizations work smarter at every level. But how exactly do these workflows […]

雲頂新耀維長寧(艾曲莫德)在中國台灣新藥上市申請獲受理 亞洲市場准入再迎里程碑

香港, 2025年8月14日 – (亞太商訊 via SeaPRwire.com) – 雲頂新耀今日宣布,中國台灣地區藥政主管部門(TFDA)已正式受理維長寧(艾曲莫德,中國台灣地區商品名:「維長寧」)用於治療中重度活動性潰瘍性結腸炎(UC)患者的新藥上市許可申請(NDA)。這一進展標志著艾曲莫…

RAK ICC以2025年立法升級加強基金會制度

阿聯酋拉斯海瑪市, 2025年8月14日 – (亞太商訊 via SeaPRwire.com) – 阿勒哈伊馬國際公司註冊中心(RAK ICC)宣布對其2019年《基金會條例》進行重大修訂,新規已於2025年7月31日生效。此次修訂是該制度自推出以來最為重要的更新之一,進一步鞏固了阿聯酋作為財富…

卫龙美味公佈2025年中期業績

香港, 2025年8月14日 – (亞太商訊 via SeaPRwire.com) – 中國辣味休閒食品行業龍頭企業,卫龙美味全球控股有限公司(「卫龙美味」或「集團」)及附屬公司(「集團」)(香港聯交所股票代碼:09985.HK)公佈截至2025年6月30日止六個月(「期內」)之中期業績。 人民…

AI Inference vs. AI Training: What Are the Differences?

SINGAPORE, Aug 13, 2025 – (ACN Newswire via SeaPRwire.com) – Artificial intelligence has many uses in daily life. From personalized shopping suggestions to voice assistants and real-time fraud detection, AI is working behind the scenes to make experiences smoother and more seamless. Behind every smart AI feature is a process that involves two distinct stages: […]

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration

HONG KONG, Aug 13, 2025 – (ACN Newswire via SeaPRwire.com) – Essex Bio-Technology Limited (“Essex” or the “Group”, Stock Code: 1061.HK) is pleased to announce that a Biologics License Application (“BLA”) for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation (“CDE”) of the National Medical […]

Re-opening of Food Expo and concurrent fairs

HONG KONG, Aug 14, 2025 – (ACN Newswire via SeaPRwire.com) – Following the lifting of the Black Rainstorm Warning Signal at 11:10am, the Food Expo, Beauty & Wellness Expo, Home Delights Expo, Food Expo PRO and Hong Kong International Tea Fair will reopen at 1:10pm. The Food Expo, Beauty & Wellness Expo, Home Delights Expo […]